Cover Image
市場調查報告書

Mesoblast Limited:產品平台分析

Mesoblast Limited - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 253823
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
Back to Top
Mesoblast Limited:產品平台分析 Mesoblast Limited - Product Pipeline Review - 2015
出版日期: 2015年10月30日 內容資訊: 英文 51 Pages
簡介

Mesoblast Limited 是活用基於細胞的技術開發廣泛領域疾病治療藥的生物科技企業。特別是免疫相關、發炎系、心血管、脊椎疾病、眼科系、神經學系、腫瘤等廣泛領域中的治療藥。

本報告提供Mesoblast Limited的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,同時也提供最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Mesoblast Limited的基本資料

Mesoblast Limited概要

  • 主要資訊
  • 企業資料

Mesoblast Limited:R&D概要

  • 主要的治療範圍

Mesoblast Limited:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Mesoblast Limited:開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Medivir AB:藥物簡介

  • JR-031
  • remestemcel-L
  • MPC-150-IM
  • MPC-CBE
  • Chondrogen
  • MPC-06-ID
  • MPC-25-Osteo
  • MPC-MICRO-IO
  • MSB-CAR-001
  • MSC-300-IV
  • Osteocel-XC
  • Allogeneic Mesenchymal Precursor Cells for Asthma and Pulmonary Fibrosis
  • Allogenic Mesenchymal Precursor Cells for Parkinson's Disease and Stroke
  • Synthetic Peptide for Cardiovascular Diseases

Mesoblast Limited:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Mesoblast Limited:最近的開發平台趨勢

Mesoblast Limited:暫停中的計劃

Mesoblast Limited:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07694CDB

Summary

Global Markets Direct's, 'Mesoblast Limited - Product Pipeline Review - 2015', provides an overview of the Mesoblast Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Mesoblast Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Mesoblast Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Mesoblast Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Mesoblast Limited's pipeline products

Reasons to buy

  • Evaluate Mesoblast Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Mesoblast Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Mesoblast Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Mesoblast Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Mesoblast Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Mesoblast Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Mesoblast Limited Snapshot
    • Mesoblast Limited Overview
    • Key Information
    • Key Facts
  • Mesoblast Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Mesoblast Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Mesoblast Limited - Pipeline Products Glance
    • Mesoblast Limited - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Mesoblast Limited - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Mesoblast Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Mesoblast Limited - Drug Profiles
    • MPC-06ID
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MPC-150IM
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MPC-25Osteo
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MPC-CBE
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • remestemcel-L
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MPC-25IC
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MPC-300IV
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MSBCAR-001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Parkinson Disease and Ishemia Stroke
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide for Cardiovascular Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide to Inhibit PAI-1 for Cardiovascular Diseases and Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Mesoblast Limited - Pipeline Analysis
    • Mesoblast Limited - Pipeline Products by Target
    • Mesoblast Limited - Pipeline Products by Route of Administration
    • Mesoblast Limited - Pipeline Products by Molecule Type
    • Mesoblast Limited - Pipeline Products by Mechanism of Action
  • Mesoblast Limited - Recent Pipeline Updates
  • Mesoblast Limited - Dormant Projects
  • Mesoblast Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Mesoblast Limited, Key Information
  • Mesoblast Limited, Key Facts
  • Mesoblast Limited - Pipeline by Indication, 2015
  • Mesoblast Limited - Pipeline by Stage of Development, 2015
  • Mesoblast Limited - Monotherapy Products in Pipeline, 2015
  • Mesoblast Limited - Phase III, 2015
  • Mesoblast Limited - Phase II, 2015
  • Mesoblast Limited - Preclinical, 2015
  • Mesoblast Limited - Pipeline by Target, 2015
  • Mesoblast Limited - Pipeline by Route of Administration, 2015
  • Mesoblast Limited - Pipeline by Molecule Type, 2015
  • Mesoblast Limited - Pipeline Products by Mechanism of Action, 2015
  • Mesoblast Limited - Recent Pipeline Updates, 2015
  • Mesoblast Limited - Dormant Developmental Projects,2015
  • Mesoblast Limited, Subsidiaries

List of Figures

  • Mesoblast Limited - Pipeline by Top 10 Indication, 2015
  • Mesoblast Limited - Pipeline by Stage of Development, 2015
  • Mesoblast Limited - Monotherapy Products in Pipeline, 2015
  • Mesoblast Limited - Pipeline by Top 10 Target, 2015
  • Mesoblast Limited - Pipeline by Top 10 Route of Administration, 2015
  • Mesoblast Limited - Pipeline by Top 10 Molecule Type, 2015
  • Mesoblast Limited - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top